EE200000148A - Kay - a new protein in the immune system - Google Patents

Kay - a new protein in the immune system

Info

Publication number
EE200000148A
EE200000148A EEP200000148A EEP200000148A EE200000148A EE 200000148 A EE200000148 A EE 200000148A EE P200000148 A EEP200000148 A EE P200000148A EE P200000148 A EEP200000148 A EE P200000148A EE 200000148 A EE200000148 A EE 200000148A
Authority
EE
Estonia
Prior art keywords
kay
immune system
new protein
protein
new
Prior art date
Application number
EEP200000148A
Other languages
Estonian (et)
Inventor
Tschopp Jurg
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200000148A publication Critical patent/EE200000148A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EEP200000148A 1997-09-12 1998-09-11 Kay - a new protein in the immune system EE200000148A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Publications (1)

Publication Number Publication Date
EE200000148A true EE200000148A (en) 2001-02-15

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000148A EE200000148A (en) 1997-09-12 1998-09-11 Kay - a new protein in the immune system

Country Status (17)

Country Link
EP (1) EP1012270A2 (en)
JP (1) JP2001515711A (en)
KR (1) KR20010023892A (en)
CN (1) CN1269832A (en)
AU (1) AU9315298A (en)
BR (1) BR9812433A (en)
CA (1) CA2303424A1 (en)
EA (1) EA200000311A1 (en)
EE (1) EE200000148A (en)
HU (1) HUP0004034A3 (en)
IL (1) IL134480A0 (en)
IS (1) IS5375A (en)
NO (1) NO20001240L (en)
PL (1) PL339740A1 (en)
SK (1) SK3532000A3 (en)
TR (1) TR200000654T2 (en)
WO (1) WO1999012964A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
CA2310987A1 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
IL144202A0 (en) 1999-01-25 2002-05-23 Biogen Inc Baff, related blocking agents and their use in the stimulation and inhibition of b-cells and immunoglobulins in immune responses
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
CA2363112A1 (en) * 1999-02-23 2000-08-31 Craig A. Rosen Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
CN100447244C (en) 1999-08-17 2008-12-31 比奥根艾迪克Ma公司 BAFF receptor (BCMA), an immunomodulator
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
CA2897626C (en) 2000-02-11 2020-03-24 Biogen Ma Inc. Heterologous polypeptide of the tnf family
WO2001087977A2 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
PT2281843T (en) 2000-06-16 2017-01-02 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
WO2002018620A2 (en) * 2000-08-15 2002-03-07 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
DK1385882T3 (en) 2001-05-11 2008-02-11 Amgen Inc Peptides and related molecules that bind to TALL-1
AR035119A1 (en) 2001-08-16 2004-04-14 Lilly Co Eli ANTI-HTNFSF13B HUMAN ANTI-BODIES
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
JP2007526220A (en) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Combination therapy for B cell disease
JP2007509064A (en) 2003-10-20 2007-04-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment regimen for BAFF antagonists
US20070249530A1 (en) * 2004-01-29 2007-10-25 Genentech, Inc. Bcma Polypeptides and Uses Thereof
BRPI0516297A (en) 2004-10-05 2008-09-02 Genentech Inc Vasculitis treatment methods and articles of manufacture
EP2332563A3 (en) 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
US7947805B2 (en) 2004-12-23 2011-05-24 Merck Serono S.A. BCMA polypeptides and uses thereof
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EP1922080A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ES2618543T3 (en) 2005-11-23 2017-06-21 Genentech, Inc. Methods and compositions related to B lymphocyte assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
BRPI0711823A2 (en) 2006-05-15 2012-01-17 Ares Trading Sa methods for treating autoimmune diseases with a taci-ig fusion molecule
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
JP5996429B2 (en) 2009-09-03 2016-09-21 ジェネンテック， インコーポレイテッド Method for treatment, diagnosis and monitoring of rheumatoid arthritis
MX353143B (en) 2011-02-28 2017-12-20 Genentech Inc Biological markers and methods for predicting response to b-cell antagonists.
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
WO2015155332A1 (en) 2014-04-11 2015-10-15 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891679A (en) * 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
WO1996040774A1 (en) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical preparations
PT939804E (en) * 1996-10-25 2005-11-30 Human Genome Sciences Inc ALPHA NEUTROQUIN
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5

Also Published As

Publication number Publication date
WO1999012964A2 (en) 1999-03-18
PL339740A1 (en) 2001-01-02
HUP0004034A3 (en) 2002-08-28
SK3532000A3 (en) 2001-12-03
JP2001515711A (en) 2001-09-25
IL134480A0 (en) 2001-04-30
EP1012270A2 (en) 2000-06-28
KR20010023892A (en) 2001-03-26
EA200000311A1 (en) 2000-10-30
BR9812433A (en) 2000-09-26
NO20001240L (en) 2000-05-10
CA2303424A1 (en) 1999-03-18
NO20001240D0 (en) 2000-03-09
TR200000654T2 (en) 2000-07-21
AU9315298A (en) 1999-03-29
IS5375A (en) 2000-02-11
HUP0004034A2 (en) 2001-03-28
WO1999012964A3 (en) 1999-05-27
CN1269832A (en) 2000-10-11

Similar Documents

Publication Publication Date Title
EE200000148A (en) Kay - a new protein in the immune system
ATE324456T1 (en) PROTEIN EXPRESSION IN BACULOVIRUS VECTOR EXPRESSION SYSTEMS
DE69704309D1 (en) Interconnects
DE69821928D1 (en) INTRA-CARDIAL DEFIBRILLING SYSTEM
DE69705170D1 (en) Interconnects
DE69822740D1 (en) Interconnects
DE69819057D1 (en) Interconnects
DE69734745D1 (en) Interconnects
DE69727259D1 (en) plane
NO985680D0 (en) peptide
DE69829560D1 (en) INTERCONNECTS
DE59710258D1 (en) connecting fitting
DE59710022D1 (en) Pipelining processor
NO983849D0 (en) peptide
DE59705833D1 (en) biaxial
DE69723647D1 (en) Interconnects
NO963487D0 (en) Isolated tyrosinase-derived peptides, and uses thereof
DE69823611D1 (en) Interconnects
DE69838828D1 (en) Interconnects
DK0865832T3 (en) sorting System
EP1018551A4 (en) MEGSINE PROTEIN
DE69719872D1 (en) Interconnects
DE69737872D1 (en) INTERCONNECTS
DE69705463D1 (en) Interconnects
DE69808562D1 (en) Interconnects